MedicalResearch.com Interview with:
Karen C. Johnston MD
Professor and Chair, Neurology
School of Medicine
University of Virginia
MedicalResearch.com: What is the background for this study?
Response: We know that acute ischemic stroke patient with hyperglycemia at presentation have worse outcomes. We also know if we lower the glucose too low that this is bad for ischemic brain also. T
he SHINE trial addressed a world wide debate about whether intensive treatment of hyperglycemia is beneficial. We assessed the efficacy and safety of an intensive glucose control protocol with a target glucose of 80-130 mg/dL compared to a more standard protocol with a target of less than 180 mg/dL.